Haruo Iguchi

3.5k total citations
107 papers, 2.6k citations indexed

About

Haruo Iguchi is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Haruo Iguchi has authored 107 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Oncology, 31 papers in Molecular Biology and 24 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Haruo Iguchi's work include Bone health and treatments (25 papers), Pancreatic and Hepatic Oncology Research (18 papers) and Neuroendocrine Tumor Research Advances (16 papers). Haruo Iguchi is often cited by papers focused on Bone health and treatments (25 papers), Pancreatic and Hepatic Oncology Research (18 papers) and Neuroendocrine Tumor Research Advances (16 papers). Haruo Iguchi collaborates with scholars based in Japan, Canada and United States. Haruo Iguchi's co-authors include Hiroshi Ibayashi, Kenichi Kato, Michel Chrétien, Hideyuki Wakasugi, Nabil G. Seidah, John S.D. Chan, Norihiro Teramoto, Soichi Takiguchi, A Funakoshi and Kyota Fujita and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Haruo Iguchi

102 papers receiving 2.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Haruo Iguchi Japan 27 1.2k 676 537 490 394 107 2.6k
Hiroaki Kuroda Japan 26 846 0.7× 537 0.8× 1.1k 2.1× 408 0.8× 276 0.7× 194 2.5k
Ronald van Eijk Netherlands 34 808 0.7× 2.0k 3.0× 395 0.7× 323 0.7× 365 0.9× 76 4.9k
Christopher R. Pierson United States 31 499 0.4× 1.1k 1.7× 366 0.7× 415 0.8× 96 0.2× 103 2.9k
Renhui Yang United States 28 352 0.3× 1.3k 1.9× 385 0.7× 319 0.7× 225 0.6× 64 2.9k
Luís Hernández Spain 40 1.5k 1.2× 1.7k 2.5× 431 0.8× 114 0.2× 182 0.5× 95 4.2k
Joseph R. Pisegna United States 24 619 0.5× 1.0k 1.5× 130 0.2× 616 1.3× 172 0.4× 53 2.6k
Hiroshi Inoué Japan 29 490 0.4× 1.0k 1.5× 793 1.5× 652 1.3× 54 0.1× 188 3.2k
Marta Couce United States 22 380 0.3× 421 0.6× 209 0.4× 338 0.7× 927 2.4× 52 2.4k
Qing Lin China 31 703 0.6× 1.2k 1.8× 198 0.4× 256 0.5× 113 0.3× 65 2.4k
Andrew Shenker United States 36 888 0.7× 2.2k 3.3× 575 1.1× 504 1.0× 93 0.2× 53 5.7k

Countries citing papers authored by Haruo Iguchi

Since Specialization
Citations

This map shows the geographic impact of Haruo Iguchi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haruo Iguchi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haruo Iguchi more than expected).

Fields of papers citing papers by Haruo Iguchi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Haruo Iguchi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haruo Iguchi. The network helps show where Haruo Iguchi may publish in the future.

Co-authorship network of co-authors of Haruo Iguchi

This figure shows the co-authorship network connecting the top 25 collaborators of Haruo Iguchi. A scholar is included among the top collaborators of Haruo Iguchi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haruo Iguchi. Haruo Iguchi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sato, Yasunori, Hideki Ueno, Tatsuya Ioka, et al.. (2018). SLCO1B1 Polymorphism Is a Drug Response Predictive Marker for Advanced Pancreatic Cancer Patients Treated With Gemcitabine, S-1, or Gemcitabine Plus S-1. Pancreas. 47(5). 637–642. 3 indexed citations
2.
Takiguchi, Soichi, Kazuko Inoue, Kimihiko Matsusue, et al.. (2017). Crizotinib, a MET inhibitor, prevents peritoneal dissemination in pancreatic cancer. International Journal of Oncology. 51(1). 184–192. 19 indexed citations
3.
Morizane, Chigusa, Takuji Okusaka, Junki Mizusawa, et al.. (2014). Randomized phase III study of gemcitabine plus S-1 combination therapy versus gemcitabine plus cisplatin combination therapy in advanced biliary tract cancer: A Japan Clinical Oncology Group study (JCOG1113).. Journal of Clinical Oncology. 32(15_suppl). TPS4149–TPS4149. 2 indexed citations
4.
5.
Asagi, Akinori, Koji Ohta, Junichirou Nasu, et al.. (2012). Utility of Contrast-Enhanced FDG-PET/CT in the Clinical Management of Pancreatic Cancer. Pancreas. 42(1). 11–19. 90 indexed citations
6.
Nasu, Junichirou, Haruo Iguchi, Akinori Asagi, Koji Ohta, & Minoru Tanada. (2010). A case of drug-induced hemolytic uremic syndrome during adjuvant chemotherapy with gemcitabine hydrochloride after resection of pancreatic cancer. Suizo. 25(2). 125–131.
7.
Seike, Toshihiro, Kyota Fujita, Yukiko Yamakawa, et al.. (2010). Interaction between lung cancer cells and astrocytes via specific inflammatory cytokines in the microenvironment of brain metastasis. Clinical & Experimental Metastasis. 28(1). 13–25. 152 indexed citations
8.
Takiguchi, Soichi, et al.. (2008). A role for leukemia inhibitory factor in melanoma-induced bone metastasis. Clinical & Experimental Metastasis. 26(2). 133–141. 25 indexed citations
9.
10.
Kimura, Yusuke, Kosuke Watari, Abbas Fotovati, et al.. (2007). Inflammatory stimuli from macrophages and cancer cells synergistically promote tumor growth and angiogenesis. Cancer Science. 98(12). 2009–2018. 108 indexed citations
11.
12.
Iguchi, Haruo. (2003). Unfinished Business. Harvard University Asia Center eBooks. 1 indexed citations
13.
Yokota, Masaki, Hirokazu Chuman, Hiroshi Harada, et al.. (2001). Increased incidence of bone metastases in hepatocellular carcinoma. European Journal of Gastroenterology & Hepatology. 13(9). 1083–1088. 150 indexed citations
14.
Wakasugi, Hideyuki, Akihiro Funakoshi, & Haruo Iguchi. (1998). Clinical assessment of pancreatic diabetes caused by chronic pancreatitis. Journal of Gastroenterology. 33(2). 254–259. 25 indexed citations
15.
Iguchi, Haruo, Kentaro Sugano, Noriko Fukayama, et al.. (1996). Analysis of Ki-ras codon 12 mutations in the duodenal juice of patients with pancreatic cancer. Gastroenterology. 110(1). 221–226. 73 indexed citations
16.
Wakasugi, Hideyuki, Hiroaki Ishikawa, Daisuke Yasuda, et al.. (1992). A Case of Pancreatic Cancer with Ascites -another diagnostic enigma-. 46(3). 225–230. 1 indexed citations
17.
Iguchi, Haruo, et al.. (1992). Production of chromogranin A and B derived peptides in human small cell lung carcinoma cell lines. European Journal of Cancer. 28(8-9). 1458–1462. 13 indexed citations
18.
Iguchi, Haruo, Nobuyuki Hara, Itsuro Hayashi, et al.. (1989). Elevation of a novel pituitary protein (7B2) in the plasma in small cell carcinoma of the lung. European Journal of Cancer and Clinical Oncology. 25(8). 1225–1232. 14 indexed citations
19.
Iguchi, Haruo, Shoichi Natori, Hajime Nawata, et al.. (1988). Plasma levels of 7B2 (a novel pituitary polypeptide) and its molecular forms in plasma and urine in patients with chronic renal failure: possible degradation by the kidney. Regulatory Peptides. 21(3-4). 263–270. 2 indexed citations
20.
Natori, Shoichi, Haruo Iguchi, Hajime Nawata, et al.. (1988). Evidence for the Release of a Novel Pituitary Polypeptide (7B2) from the Growth Hormone-Producing Pituitary Adenoma of Patients with Acromegaly*. The Journal of Clinical Endocrinology & Metabolism. 66(2). 430–437. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hiroaki Kuroda Breakdown of academic impact, for papers by Ronald van Eijk Breakdown of academic impact, for papers by Christopher R. Pierson Breakdown of academic impact, for papers by Renhui Yang Breakdown of academic impact, for papers by Luís Hernández Breakdown of academic impact, for papers by Joseph R. Pisegna Breakdown of academic impact, for papers by Hiroshi Inoué Breakdown of academic impact, for papers by Marta Couce Breakdown of academic impact, for papers by Qing Lin Breakdown of academic impact, for papers by Andrew Shenker
Rankless by CCL
2026